JZJian Zhang

Jian Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jian Zhang has a total of 184 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The conversion of pulmonary artery smooth muscle cells to eosinophil-like cells exacerbates the progression of pulmonary arterial hypertension with increased secretion of 12-HETE

    by Zhiang Jiao, Gang Xu, Fengyuan Zhu, Yu Zhang, Junyan Xu, Zonghao Chen, Anqi Yan, Minghui Piao, Zhengwei Dong, Lei Chen, et al.

  • Inhibiting RhoA Activation Via GDP-State Stabilization to Relieve Heart Failure

    by Mengzhu Xue, Yingquan Liang, Zhen Yuan, Xiangning Liu, Longfeng Chang, Yongzhi Wang, Peijia Xu, Tingting Zhang, Hewei Jiang, Zijie Zhao, et al.

    BACKGROUND: Given the persistently high morbidity and mortality of heart failure (HF), targeting myocardial remodeling, particularly pathological hypertrophy and fibrosis, has become a major therapeutic priority. RhoA (Ras homolog gene family member A), a small GTPase governing cytoskeletal reorganization and cell migration, plays a pivotal role in this process. However, RhoA has long been considered undruggable because of its high-affinity binding to GDP/GTP and the absence of well-defined druggable pockets. METHODS: Structural analyses comparing RhoA-GTP and RhoA-GDP conformations, combined with surface plasmon resonance-based screening, were used to identify a RhoA inhibitor. The underlying mechanism was validated in cultured cells and 3-dimensional myocardial tissue models. Therapeutic efficacy was assessed across multiple species of HF models and supported by multiomics analyses linking RhoA activation to human HF. Key findings were further confirmed by multiplex immunohistochemistry and pulldown assays in human heart specimens. RESULTS: We identified an unrecognized cryptic pocket adjacent to GDP in RhoA. A natural product, AH001, selectively occupied this pocket and interacted with GDP, thereby stabilizing the interaction between RhoA and its endogenous inhibitor, RhoGDIÎą (Rho GDP-dissociation inhibitor 1). AH001 suppressed downstream signaling by reducing MRTFA (myocardin-related transcription factor A) nuclear translocation and downregulating fibrosis- and hypertrophy-related proteins. Moreover, AH001 disrupted pathological crosstalk between Mrtfa + cardiomyocytes and fibroblasts. Consequently, AH001 markedly attenuated myocardial remodeling in multiple HF animal models, as well as in 3-dimensional myocardial tissue models. CONCLUSIONS: These findings establish pharmacological inhibition of RhoA activation as a viable strategy to mitigate myocardial remodeling in HF and provide a conceptual framework for developing reversible inhibitors against previously undruggable small GTPases.


  • Open Access

    Deletion of RhoGDI Protects Against Hepatic Steatosis via Improved Mitochondrial Metabolism in Mice

    by Yongzhi Wang, Yuanqi Zhou, Yifan Xu, Chen Wang, Shuo Meng, Honglin Li, Huifang Tang, Jian Zhang

    The global incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising alongside epidemics of diabetes and obesity. Rho GDP-dissociation inhibitor (RhoGDI) is now recognized to play dual regulatory roles in disease. A deeper understanding of its mechanistic contributions in MASLD could offer critical insights for developing novel therapies against this growing health burden. Immunohistochemical staining was used to examine RhoGDI expression in liver tissues from patients with MASLD. Hepatocyte-specific deletion of Arhgdia (the gene encodes RhoGDI) was generated in mice, and they subjected to NASH diets to induce hepatic steatosis. Transcriptomic sequencing was carried out to identify altered pathways in the Arhgdia-deficient mice, followed by functional investigations of downstream signaling and mitochondrial performance. Finally, the therapeutic potential of a candidate compound was evaluated in the MASLD model. The expression level of RhoGDI was significantly upregulated, and hepatocyte-specific deletion of Arhgdia (the gene encodes RhoGDI) attenuated hepatic lipid accumulation and fibrotic progression. The RNA sequencing analysis revealed that RhoGDI deficiency suppressed the hepatic steroid hormone biosynthesis pathway. It was demonstrated that RhoGDI plays a crucial role in maintaining mitochondrial function, since hepatocyte-specific knockout of Arhgdia significantly reversed mitochondrial dysfunction in mice. Furthermore, a natural compound was found to alleviate hepatic steatosis and inflammation in MASLD mice by targeting RhoGDI. This finding demonstrates that Arhgdia deletion confers protection against the progression of MASLD by reducing hepatic lipid accumulation and enhances mitochondrial β-oxidation in hepatocytes establishing RhoGDI as a critical regulator of MASLD pathogenesis and highlighting its potential as a therapeutic target for metabolic liver diseases.

  • Open Access

    Editorial: Efficacy and mechanism of herbal medicines and their functional compounds in preventing and treating cardiovascular diseases and cardiovascular disease risk factors-Volume II

    by Tiantian Meng, Yuqing Zhang, Jie Wang, Chen Huei Leo, Zhongfeng Li, Jian Zhang, Kuo Gao, Qingyong He

    According to the latest statistics, cardiovascular diseases (CVDs) continue to be the primary cause of morbidity and death globally (Li et al., 2025;Mensah et al., 2023). Despite significant advancements in conventional pharmacotherapy and interventional strategies, the global burden of CVDs and their associated risk factors-such as diabetes, hypertension, and dyslipidemia-continues to rise (Global Burden of Cardiovascular Diseases andRisks 2023 Collaborators, 2025). Between 2025 and 2050, projections suggest a 90.0% increase in CVD prevalence, a 73.4% rise in the crude mortality rate, with deaths expected to reach 35.6 million, highlighting the critical requirement for alternative or complementary therapeutic strategies (Chong et al., 2025). Herbal medicines, with a history of thousands of years in traditional medical systems, have emerged as promising candidates for their multi-component, multi-target characteristics, and relatively favorable safety profiles compared to certain synthetic drugs (Yan et al., 2023).In recent decades, increasing evidence from preclinical and clinical studies has illuminated the efficacy of herbal medicines and their bioactive compounds in modulating key pathological processes underlying CVDs, such as inflammation, oxidative stress, endothelial dysfunction, and myocardial remodeling (Cao et al., 2024;Huang et al., 2025;Yan et al., 2023;Zhang et al., 2025). Nonetheless, systematic integration of these fragmented findings and a thorough investigation of their molecular mechanisms are crucial for translating traditional knowledge into evidence-based clinical practice. To address this gap, we organized the special issue.A total of 76 manuscripts were received, and after a rigorous peer-review process, this special issue successfully compiled 14 high-quality articles, encompassing original research studies and comprehensive reviews.Dyslipidemia, commonly referred to as hyperlipidemia, is primarily defined by elevated levels of total cholesterol (TC, ≥ 200 mg/dL), triglycerides (TG, ≥ 150 mg/dL), and low-density lipoprotein cholesterol (LDL-C, ≥ 160 mg/dL ) in the bloodstream, or by reduced levels of high-density lipoprotein cholesterol (HDL-C, < 40 mg/dL in male or < 50 mg/dL in female). This condition is recognized as a significant risk factor for CVDs (Zeljkovic et al., 2024).Shi et al. performed a meta-analysis of 33 randomized controlled trials (RCTs) to evaluate the clinical efficacy of red yeast rice-containing Chinese polyherbal preparations in the treatment of dyslipidemia. The pooled results indicated that the combined preparations significantly reduced TC, TG, and LDL-C, while increasing HDL-C compared to statin therapy alone. Tian et al. reviewed the clinical efficacy and mechanisms of action of the classic traditional Chinese medicine (TCM) prescription Erchen decoction in treating hyperlipidemia. Previous clinical studies have shown that Erchen decoction and its modified formulations can reduce the levels of TG, TC, and LDL-C. Mechanistically, Erchen decoction primarily enhances lipid metabolism, regulates oxidative stress, and suppresses inflammation. Its active components mainly include β-sitosterol, Poria cocos polysaccharides, glycyrrhetinic acid, gingerol, oleanolic acid, and ursolic acid. Tang et al. systematically investigated the active ingredients and mechanisms of the BuShao Tiaozhi capsule for hyperlipidemia treatment. The findings indicated that BuShao Tiaozhi capsule effectively alleviates lipid metabolism disorders by blocking the Phosphatidylinositol 3-Kinase /Protein Kinase B (PI3K/Akt) pathway.Hypertensive heart disease (HHD) is a secondary cardiac condition characterized by pathological alterations in cardiac structure and function, resulting from prolonged exposure to hypertension. It represents one of the most prevalent forms of target organ damage of hypertension and may eventually progress to heart failure (Díez et al., 2023).An SR conducted by Hui et al. encompassed 21 RCTs, aiming to evaluate the clinical efficacy of specific TCM interventions designed to replenish qi and activate blood circulation as adjunctive treatments for hypertensive heart disease. The findings revealed that the combination of TCM and western medicine outperforms western medicine alone in enhancing cardiac function and alleviating adverse left ventricular remodeling. Notably, Danshen, Chuanxiong, Gegen, Huangqi, and Puhuang are the five most frequently utilized Chinese herbal medicines.Coronary heart disease (CHD), commonly referred to as ischemic heart disease, includes acute coronary syndrome (such as unstable angina pectoris and myocardial infarction) and chronic coronary syndrome. It represents the leading cause of age-standardized mortality globally (Virani et al., 2023;Rao et al., 2025).Six systematic reviews (SRs) have examined the effectiveness of herbal medicines in treating CHD. Wang et al.'s SR found that the modified Danggui Sini decoction, as an adjunct treatment, can shorten the duration of angina pectoris attacks, lower N-terminal pro-B-type natriuretic peptide levels, and improve the Seattle Angina Questionnaire scores in patients with CHD. Dai et al. performed a network meta-analysis comparing the clinical efficacy of ten different Danshen class injections for treating CHD. Their findings revealed that the combination of Danshen class injections with western medicine outperformed the use of western medicine alone. Specifically, Danshenduofensuanyan injection and Danshenchuanxiongqin injection demonstrated superior anti-inflammatory effects, while Danhong injection exhibited greater antioxidative properties. An SR by Chen et al. reported the efficacy of Salvianolate for injection, a Danshen-derived metabolite, as an adjunctive therapy for acute myocardial infarction. The pooled results from 30 RCTs involving 3,931 cases indicated that the combined use of Salvianolate for injection alongside western...

  • Open Access

    Protective effects of biomimetic Cu-Zn-MOF against DOX-Induced cardiotoxicity through inhibiting oxidative stress and ferroptosis

    by Jian Wang, Meng Zhao, Jian Zhang, Xiaoyan Zhang, Hongming Zhu, Changnan Wang, Song Zhang

    Doxorubicin (DOX), a member of the anthracycline family, is widely recognized as an effective chemotherapeutic agent for cancer treatment. However, its cli


  • Open Access

    Leucine‐Dependent SLC7A5–PGAM5 Interaction Promotes Advanced Atherosclerosis Through Hindering Mitochondrial Function of Macrophages

    by Shan Zhong, Xueyu Wang, Qingsong Li, Siqi Wang, Bin Sun, Wenjun Ni, Gengyu Zhou, Fan Wang, Xianwei Xie, Cheng Jin, et al.

    The residual risks of advanced atherosclerosis remain substantial despite current preventive strategies and pharmacotherapy. Circulating branched‐chain amino acids are biomarkers of cardiovascular disease risk. However, the mechanism of leucine in atherosclerosis progression remains unclear. Leucine transporter‐SLC7A5‐mediated leucine intake that promotes advanced atherosclerosis in mice, increasing apoptotic macrophages and lipids accumulation within plaques. Multi‐omics analyses showed that leucine deprivation enhanced macrophage mitochondrial function and increased plaque CD5L hi macrophages, under SLC7A5‐deficiency‐mediated leucine deprivation, these cells exhibited stronger oxidative phosphorylation and lipid metabolism. Mechanistically, leucine deficiency reduced SLC7A5‐PGAM5 binding in macrophages, promoting PGAM5‐NDUFV1 interaction and enhancing mitochondrial function, which attenuates atherosclerosis progression. Collectively, these findings elucidate the function and mechanism of SLC7A5 in Cd5l hi macrophages, highlighting it as a potential therapeutic target. Strategies aimed at improving mitochondrial function also offer a promising approach for advanced atherosclerosis treatment.


  • Top Cited Papers

    Inactivation of RhoA for Hypertension Treatment Through the TRPV4–RhoA–RhoGDI1 Axis

    by Jiawen Wang, Zhen Yuan, Na Yu, Qian Jiao, Honglei Zhou, Wenjie Liao, Jiwei Shan, Shanshan Ruan, Yi Zhao, Ya Mo, et al.

    BACKGROUND: The RhoA (Ras homolog family member A) signaling pathway is pivotal in regulating vascular smooth muscle cells (VSMCs) function and blood pressure homeostasis. Current inhibitors of the RhoA signaling pathway are limited in hypertension treatment, suffering from poor efficacy, insufficient specificity, and developmental challenges. METHODS: Cryo-electron microscopy (EM), proximity ligation assay (PLA), and site-directed mutagenesis were used to explore the mechanism of RhoA activity regulation. VSMC, hypertensive animal models, Trpv4 -/- and Arhgdia f/f Myh11-CRE ERT2 (smooth muscle–specific RhoGDI1 knockout) mice were used to investigate the role of the TRPV4 (transient receptor potential cation channel subfamily V member 4)–RhoA–RhoGDI1 (Rho GDP dissociation inhibitor 1) axis in hypertension. RESULTS: AH001 (( R )-1-(3-ethylphenyl) ethane-1,2-diol) was identified as a novel inhibitor of the RhoA signaling pathway. It targets the TRPV4–RhoA–RhoGDI1 axis to effectively sequester inactive RhoA–GDP in the plasma membrane and cytoplasm, which is distinct from typical RhoA inhibition modes. The cryo-EM structure of the TRPV4 AH001 –RhoA complex showed that AH001-bound TRPV4 adopts a closed state with RhoA in an inactive GDP-bound state. Functional studies further revealed that AH001 reduced the pool of active RhoA by enhancing TRPV4–RhoA binding and facilitating RhoGDI1–RhoA interaction in VSMC. This inhibition notably decreased both acute and long-term blood pressure and prevented vascular remodeling in Ang II–induced hypertensive mice and spontaneously hypertensive rats. However, these antihypertensive effects were weakened in Trpv4 -/- and Arhgdia f/f Myh11-CRE ERT2 mice. Additionally, AH001 effectively inhibited VSMC contraction via the RhoA/ROCK (Rho-associated protein kinase)/MYPT1 (myosin phosphatase target subunit 1)/MLC (myosin light chain 2) signaling pathway and suppressed VSMC phenotype switching to myofibroblasts through the RhoA/ROCK/LIMK1 (LIM domain kinase)/cofilin/MRTF-A (myocardin-related transcription factor A)/SRF (serum response factor) signaling cascade. TRPV4 and RhoGDI1 knockdown attenuated AH001’s inhibition of VSMC contraction and phenotypic switching to myofibroblasts. CONCLUSIONS: This study revealed a novel mode of RhoA signaling inhibition targeting the TRPV4–RhoA–RhoGDI1 axis, offering new insights for future antihypertensive drug development and proposing innovative strategies for targeting challenging Rho GTPases.


  • HMOX1-LDHB interaction promotes ferroptosis by inducing mitochondrial dysfunction in foamy macrophages during advanced atherosclerosis

    by Xiang Peng, Bin Sun, Chaohui Tang, Chengyu Shi, Xianwei Xie, Xueyu Wang, Dingsheng Jiang, Shuo Li, Ying Jia, Yani Wang, et al.


  • Open Access

    Herbal medicine formula Huazhuo Tiaozhi granule ameliorates dyslipidaemia via regulating histone lactylation and miR-155-5p biogenesis

    by Xiangjun Yin, Min Li, Yongzhi Wang, Guifang Zhao, Tao Yang, Yuqing Zhang, Jianbo Guo, Tiantian Meng, Ruolin Du, Honglin Li, et al.

    Background: Huazhuo Tiaozhi granule (HTG) is a herbal medicine formula widely used in clinical practice for hypolipidaemic effects. However, the molecular mechanisms underlying dyslipidaemia treatment have not been well elucidated. Results: A significant reduction in the levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) was observed in the serum of patients with dyslipidaemia after HTG treatment, without disruption in the levels of aspartate transaminase (AST), alanine transaminase (ALT), urea nitrogen (BUN), and creatinine (Cr). The dyslipidaemia rat model was induced by a high-fat diet and treated with Xuezhikang (0.14 g/kg/d) or HTG (9.33 g crude herb/kg/day) by gavage for 8 weeks. Body weight and liver index were markedly decreased in dyslipidaemic rats after treatment with Xuezhikang or HTG. HTG administration markedly ameliorated hyperlipidaemia by decreasing the levels of TC and LDL-C in serum and hepatic lipid accumulation. In vitro, lipid accumulation in LO2 and HepG2 cells was alleviated by serum treatment with HTG. High lactylation was observed in 198 proteins, including lactylation of histone H2B (K6), H4 (K80). Deep sequencing of microRNAs showed that miR-155-5p was significantly downregulated. Conclusions: This study demonstrates that HTG is an effective and safe formula for treating dyslipidaemia, which promotes lactylation in hepatocytes, and the retardation of miR-155-5p biogenesis. Graphical


  • Long Noncoding RNA Gpr137b-ps Promotes Advanced Atherosclerosis via the Regulation of Autophagy in Macrophages

    by Wenbo Qu, Xin Zhou, Xinjian Jiang, Xianwei Xie, Kaijian Xu, Xia Gu, Ruisi Na, Minghui Piao, Xiangwen Xi, Na Sun, et al.

    BACKGROUND: Current therapies cannot completely reverse advanced atherosclerosis. High levels of amino acids, induced by Western diet, stimulate mTORC1 (mammalian target of rapamycin complex 1)-autophagy defects in macrophages, accelerating atherosclerotic plaque progression. In addition, autophagy-lysosomal dysfunction contributes to plaque necrotic core enlargement and lipid accumulation. Therefore, it is essential to investigate the novel mechanism and molecules to reverse amino acid–mTORC1–autophagy signaling dysfunction in macrophages of patients with advanced atherosclerosis. METHODS: We observed that Gpr137b-ps (G-protein–coupled receptor 137B, pseudogene) was upregulated in advanced atherosclerotic plaques. The effect of Gpr137b-ps on the progression of atherosclerosis was studied by generating advanced plaques in ApoE −/− mice with cardiac-specific knockout of Gpr137b-ps. Bone marrow–derived macrophages and mouse mononuclear macrophage cell line RAW264.7 cells were subjected to starvation or amino acid stimulation to study amino acid–mTORC1–autophagy signaling. Using both gain- and loss-of-function approaches, we explored the mechanism of Gpr137b-ps–regulated autophagy. RESULTS: Our results demonstrated that Gpr137b-ps deficiency led to enhanced autophagy in macrophages and reduced atherosclerotic lesions, characterized by fewer necrotic cores and less lipid accumulation. Knockdown of Gpr137b-ps increased autophagy and prevented amino acid–induced mTORC1 signaling activation. As the downstream binding protein of Gpr137b-ps, HSC70 (heat shock cognate 70) rescued the impaired autophagy induced by Gpr137b-ps. Furthermore, Gpr137b-ps interfered with the HSC70 binding to G3BP (Ras GTPase-activating protein-binding protein), which tethers the TSC (tuberous sclerosis complex) complex to lysosomes and suppresses mTORC1 signaling. In addition to verifying that the NTF2 (nuclear transport factor 2) domain of G3BP binds to HSC70 by in vitro protein synthesis, we further demonstrated that HSC70 binds to the NTF2 domain of G3BP through its W90-F92 motif by using computational modeling. CONCLUSIONS: These findings reveal that Gpr137b-ps plays an essential role in the regulation of macrophage autophagy, which is crucial for the progression of advanced atherosclerosis. Gpr137b-ps impairs the interaction of HSC70 with G3BP to regulate amino acid–mTORC1–autophagy signaling, and these results provide a new potential therapeutic direction for the treatment of advanced atherosclerosis.